Reported 2 days ago
ClearBridge Investments highlighted Vertex Pharmaceuticals (NASDAQ:VRTX) in its Q3 2025 investor letter due to its leading position in cystic fibrosis therapies and potential in pain treatment. Despite a recent decline in stock value, the firm believes its moderate valuation presents a buying opportunity. Vertex reported $2.96 billion in revenue for Q2 2025, a 12% increase from the previous year, although it is not among the top picks for hedge funds currently.
Source: YAHOO